Advanced search
Publication Cover
HIV Clinical Trials Volume 3, 2002 - Issue 4
Submit an article Journal homepage
28
Views
0
CrossRef citations to date
0
Altmetric
Original Articles

Matrix Metalloproteinase-9 and Tissue Inhibitors of Matrix Metalloproteinase-1 in Plasma of Patients Co-Infected with HCV and HIV

Claudio M. MastroianniDepartment of Infectious and Tropical Diseases, La Sapienza University, RomeCorrespondence[email protected]
,
Grazia M. LiuzziDepartment of Biochemistry and Molecular BiologyUniversity of Bari, Bari
,
Gabriella, d’EttorreDepartment of Infectious and Tropical Diseases, La Sapienza University, Rome
,
Miriam LichtnerDepartment of Infectious and Tropical Diseases, La Sapienza University, Rome
,
Gabriele ForcinaDepartment of Infectious and Tropical Diseases, La Sapienza University, Rome
,
Nicola Francesco Di CampliDepartment of Infectious and Tropical Diseases, La Sapienza University, Rome
,
Paolo RiccioDepartment of BiologyD.B.A.F., University of Basilicata, Potenza, Italy
&
Vincenzo VulloDepartment of Infectious and Tropical Diseases, La Sapienza University, Rome
 show all
Pages 310-315 | Published online: 14 Jan 2015

REFERENCES

  • Sulkowski MS. Hepatitis C virus infection in HIV-infected patients. Curr Infect Dis Rep. 2001;5:469–476.
  • Sulkowski MS, Mast EE, Seeff LB, Thomas DL. Hepatitis C virus infection as an opportunistic disease in persons in-fected with human immunodeficiency virus. Clin Infect Dis. 2000;30\(suppl 1):S77–84.
  • Monga HK, Rodriguez-Barradas MC, et al. Hepatitis C virus infection-related morbidity and mortality among pa-tients with human immunodeficiency virus infection. Clin Infect Dis. 2001;33:240–247.
  • Puoti M, Bonacini M, Spinetti A, et al. Liver fibrosis pro-gression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and human immunodefi-ciency virus. J Infect Dis. 2001183: 134–137.
  • Arthur MJP. Matrix degradation in the liver. Semin Liver Dis. 1990;10:47–55.
  • Woessner JF Jr. MMPs and TIMPs. An historical perspec-tive. Methods Mol Biol. 2001151: 1–23.
  • Iredale JP. Tissue inhibitors of metalloproteinases in liver fibrosis. Int J Biochem Cell Biol. 1997;29:43–54.
  • Arthur MJP. Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis. Am J Physiol Gastrointest Liver Physiol. 2000;279:G245–249.
  • Walsh KM, Timms P, Campbell S, MacSween RN, Morris AJ. Plasma levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of metalloproteinases-1 and -2 (TIMP-1 and TIMP-2) as noninvasive markers of liver disease in chronic hepatitis C: comparison using ROC analysis. Dig Dis Sci. 1999;44:624–630.
  • Mitsuda A, Suou T, Ikuta Y, Kawasaki H. Changes in serum tissue inhibitor of matrix metalloproteinase-1 after inter-feron alpha treatment in chronic hepatitis C. J HepatoL 2000;32:666–672.
  • Lichtinghagen R, Michels D, Haberkorn Cl, et al. Matrix metalloproteinase (MMP)-2, MMP-7, and tissue inhibitor of metalloproteinase-1 are closely related to the fibroproliferative process in the liver during chronic hepati-tis C. J Hepatol. 2001;34:239–247.
  • Weeks BS. The role of HIV-1 activated leukocyte adhesion mechanisms and matrix metalloproteinases secretion in AIDS pathogenesis. Int J Mol Med. 1998;1:361–366.
  • Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J HepatoL 1995;22:696–699.
  • Liuzzi GM, Mastroianni CM, Santacroce MP, et al. In-creased activity of matrix metalloproteinases in the cere-brospinal fluid of patients with HIV-associated neurological diseases. J Neurovirol. 2000;6:156–163.
  • Bice I, McGovern B, Dhar R. Increasing mortality due to end-stage liver disease in patients with human immunode-ficiency virus infection. Clin Infect Dis. 2001;32:492–497.
  • McCrudden R, Iredale JP. Liver fibrosis, the hepatic stellate cell and tissue inhibitors of metalloproteinases. Histol Histopathol. 2000;15:1159–1168.
  • Lichtinghagen R, Huegel O, Seifert T, et al. Expression of matrix metalloproteinase-2 and -9 and their inhibitors in peripheral blood cells of patients with chronic hepatitis C. Clin Chem. 2000;46:183–192.
  • Benhamou Y, Di Martino V, Bochet M, et al. Factors affect-ing liver fibrosis in human immunodeficiency virus- and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology. 2001;34:283–287.
  • Bonacini M. Management issues in patients coinfected with hepatitis C virus and HIV. AIDS Read. 2002;12:19–26.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.